EMBO Molecular Medicine (Jan 2022)

Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host

  • Kyung‐Soo Lee,
  • Jieun Lee,
  • Pureum Lee,
  • Bong Chan Jeon,
  • Min Yeong Song,
  • Sojung Kwak,
  • Jungwoon Lee,
  • Jun‐Seob Kim,
  • Doo‐Jin Kim,
  • Ji Hyung Kim,
  • Vernon L Tesh,
  • Moo‐Seung Lee,
  • Sung‐Kyun Park

DOI
https://doi.org/10.15252/emmm.202114678
Journal volume & issue
Vol. 14, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Shiga toxins (Stxs) produced by enterohemorrhagic Escherichia coli (EHEC) are the major virulence factors responsible for hemorrhagic colitis, which can lead to life‐threatening systemic complications including acute renal failure (hemolytic uremic syndrome) and neuropathy. Here, we report that O‐GlcNAcylation, a type of post‐translational modification, was acutely increased upon induction of endoplasmic reticulum (ER) stress in host cells by Stxs. Suppression of the abnormal Stx‐mediated increase in O‐GlcNAcylation effectively inhibited apoptotic and inflammatory responses in Stx‐susceptible cells. The protective effect of O‐GlcNAc inhibition for Stx‐mediated pathogenic responses was also verified using three‐dimensional (3D)‐cultured spheroids or organoids mimicking the human kidney. Treatment with an O‐GlcNAcylation inhibitor remarkably improved the major disease symptoms and survival rate for mice intraperitoneally injected with a lethal dose of Stx. In conclusion, this study elucidates O‐GlcNAcylation‐dependent pathogenic mechanisms of Stxs and demonstrates that inhibition of aberrant O‐GlcNAcylation is a potential approach to treat Stx‐mediated diseases.

Keywords